(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number
WO 2004/096777 A1

(51) International Patent Classification[7]: C07D 239/42, 403/12, 405/12, 401/12, 407/12, 403/04, 403/14, 239/34, 239/48, A61K 31/506, A61P 11/06

(21) International Application Number:
PCT/EP2004/003910

(22) International Filing Date: 14 April 2004 (14.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03009384.3 25 April 2003 (25.04.2003) EP

(71) Applicant *(for all designated States except US)*: **BAYER HEALTHCARE AG** [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LY, Tai-wei** [CA/JP]; 329-1-211, Kodono-cho, Nara-shi, Nara 630-8441 (JP). **KORIYAMA, Yuji** [JP/JP]; 5-13-6-102, Jingu, Nara-shi, Nara 630-0804 (JP). **YOSHINO, Takashi** [JP/JP]; 1-1-17-101, Saidaiji, Nogami-cho, Nara-shi, Nara 631-0833 (JP). **SATO, Hiroki** [JP/JP]; 4-7-4-102, Jingu, Nara-shi, Nara 631-0804 (JP). **TANAKA, Kazuho** [JP/JP]; 15-1-301, Konyama-cho, Yamato, Koriyama-shi, Nara 639-1148 (JP). **SUGIMOTO, Hiromi** [JP/JP]; 4-25-2-B201, Sakuragaoka, Seika-cho, Sorakui-gun, Kyoto 619-0232 (JP). **MANABE, Yoshihisa** [JP/JP]; 4-8-19, Suzaku, Nara-shi, Nara 631-0806 (JP). **BACON, Kevin** [GB/JP]; 5-15-912, Koyo-cho, Naka, Higashinada-ku, Kobe-shi, Hyogo 658-0032 (JP). **URBAHNS, Klaus** [DE/JP]; 6-3-1-301, Kusugaoka-cho, Nada-ku, Kobe-shi, Hyogo 657-0024 (JP). **SEKI, Masanori** [JP/JP]; 7-17-202, Sanjo-sakae-machi, Nara-shi, Nara 630-8126 (JP). **SHINTANI, Takuya** [JP/JP]; 4-24-1, Seikadai, Seika-cho, Soraku-gun, Kyoto 619-0238 (JP).

(74) Common Representative: **BAYER HEALTHCARE AG**; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2



(I)

(57) Abstract: The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.

WO 2004/096777 A1